Skip to main content

Advertisement

Table 2 The responses of 40 Chinese patients with mCRC to the SOL regimen

From: Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer

Response No. of patients [cases (%)]
Complete response 0
Partial response 20 (50.0)
Stable disease 12 (30.0)
Disease control 32 (80.0)
Progression 3 (7.5)
Not evaluable 5 (12.5)
Overall responsea 20 (50.0)
  1. SOL the combination of S-1, oxaliplatin, and leucovorin regimen. Other abbreviation as in Table 1
  2. a95% confidence interval of overall response rate is 33.8%–66.2%